Pelican Therapeutics, a Subsidiary of Heat Biologics, Receives First Tranche of $15.2 Million CPRIT Grant Award

DURHAM, NC  / June 28, 2017 / Heat Biologics, Inc. ("Heat") (NASDAQ: HTBX), a leader in the development of novel therapies designed to activate a patient's immune system against cancer, reported that its Pelican Therapeutics subsidiary is on track to meet product development milestones and has received the first tranche of its $15.2 million Cancer Prevention and Research Institute of Texas (CPRIT) grant award.
 
"We have made significant progress in advancing PTX-25, our lead antibody, towards the clinic, having completed key milestones, including epitope mapping, affinity maturation and antibody development studies," said Jeff Wolf, Founder and CEO of Heat. "We are pleased that Pelican has received the first tranche of its CPRIT award, which provides non-dilutive funding to cover costs of IND-enabling studies towards a comprehensive, 70-patient Phase 1 clinical trial combining PTX-25 with other immune-oncology drugs"
Read more: Heat Biologics Inc ( HTBX )

Silvercorp net income $43.7 million, $0.26 per share, for Fiscal 2017

VANCOUVER, May 25, 2017 - Silvercorp Metals Inc. ("Silvercorp" or the "Company") (TSX: SVM) (NYSE: SVM) reported its financial and operating results for the fourth quarter and twelve months ended March 31, 2017.  All amounts are expressed in US Dollars.
 
FISCAL YEAR 2017 HIGHLIGHTS
Net income attributable to equity shareholders of $43.7 million, or $0.26 per share1, up 589% compared to net income attributable to equity shareholders of $6.3 million, or $0.04 per share in the prior year. Adjusted net income2 attributable to equity shareholders of $38.6 million or $0.23 per share, up 509% from the prior year after adjustment to one-time net impairment reversal of $5.1 million;
Read more: Silvercorp Metals ( SVM )

Cellular Biomedicine Group (CBMG) Announces Publication Titled “Target cell killing effects of CD20 targeting chimeric antigen receptor T cells derived from the type II anti-CD20 antibody ” in Conjunction with 2017 ASCO Annual Meeting

SHANGHAI, China and CUPERTINO, Calif., May 19, 2017  -- Cellular Biomedicine Group Inc. (NASDAQ:CBMG) (“CBMG” or the “Company”), a clinical-stage biopharmaceutical firm engaged in the development of effective immunotherapies for cancer and stem cell therapies for degenerative diseases, today announced the publication of an abstract exploring the application of B-cell antigen, CD20, for targeted Chimeric Antigen Receptor T cells (CAR-T) therapy. The abstract has been published in conjunction with the 2017 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, June 2 – 6, 2017. 
Read more: Cellular Biomedicine Group ( CBMG )

ENSERVCO Reports First Quarter 2017 Financial Results

DENVER, CO--(May 11, 2017) - ENSERVCO (NYSE MKT: ENSV)
 
Revenue increases 66% to $13.8 million from $8.3 million year over year
Net income improved to $50,000 versus a net loss of $1.1 million year over year
Adjusted EBITDA increases 281% to $2.5 million from $661,000 year over year
Well enhancement service revenue increases 67% to $12.0 million from $7.2 million year over year
New water transfer service revenue increases 393% to $752,000 in Q1 from $153,000 in Q4 2016
Revenue from Eagle Ford expansion increases 61% to $1.4 million from $867,000 year over year
Read more: ENSERVCO Corporation ( ENSV )

Dynacor Produces 17,125 oz of Gold in Q1-2017

MONTREAL, QUEBEC--( April 20, 2017) - Dynacor Gold Mines Inc. (TSX:DNG) (OTC:DNGDF) (Dynacor or the Corporation) is pleased to report that its 1st quarter gold production reached 17,125 oz. This represents an increase of 1,318 ounces of gold, as compared to Q1-2016 (15,807 oz), despite the extreme weather conditions in northern and central Peru which has led to the destruction of many bridges and roads and localized severe flooding.
 
Total gold exported during Q1-2017 was 20,301 oz. 
Monthly gold production data in 2017 and 2016 for the first quarter are presented in the Table 1 below. As compared to 2016, gold production was higher in January (+15%) and reached an all-time high for a month of February (+31%) but due to the extreme weather and its impact, production was lower in March (-16%). Nevertheless, total quarterly gold production increased by 8.3% (1,318 oz). 
Read more: Dynacor Gold Mines ( DNG )